Dr. Jonathan Javitt, Founder, Chairman and CEO, NeuroRx talks about drawing on their work developing novel therapeutics for bipolar depression and respiratory disease to focus on a therapy, aviptadil also known as ZYESAMI, for critical COVID-19 especially those with advanced comorbidities. This peptide hormone VIP enters the alveolar type II rare cell in the lung and blocks the replication of the SARs-CoV-2 virus and the production of inflammatory cytokines. Available through the FDA Expanded Access protocol, this drug is showing a nine-fold difference in survival and recovery from respiratory failure compared to patients with best available standard of care.
@neurorxpharma #aviptadil #RLF-100 #ZYESAMI #coronavirus #COVID19 #drugdevelopment #pandemic $NRXP
NeuroRxPharma.com
Download the transcript here
Empowered Patient Podcast